Two split influenza virus vaccines administered intragastrically induced lower titres of haemagglutinin (HA)-specific antibodies in pulmonary secretions than whole virus vaccine or a third split virus vaccine. IgA antibody was the predominant HA-specific Ig class. HA-specific IgA titres decayed substantially within 2 weeks following booster immunization, but persisted for at least another 3.5 months. In contrast, HA-specific IgG was maintained at low titres throughout the 4 month study period. When the total vaccine antigenic mass was administered as one dose or as equally divided doses spread over several days, pulmonary antibody responses were comparable. Mice immunized intragastrically with whole virus vaccine were completely protected against intranasal challenge with a homologous virulent virus of the H3 subtype. Partial protection was obtained when the vaccine used for immunization was a distantly related, antigenically variant strain of the same subtype, but no protection was obtained with a monovalent vaccine of an influenza A subtype different to the challenge virus. These characteristics of the response to intragastric immunization against influenza are consistent with features of a useful vaccine.
INTRODUCTION
Antibodies reactive with the haemagglutinin (HA) of influenza virus neutralize viral infectivity (Laver & Kilbourne, 1966) . Virus-specific neutralizing antibodies, especially of the IgA isotype, play an important role in controlling influenza virus infection of the respiratory tract (Liew et al., 1984) . Production of secretory IgA in bronchial secretions is achieved by intranasal immunization with either live or inactivated influenza virus (Laver & Kilbourne, 1966; Snyder et al., 1986; Waldman et al., 1968) , as well as by oral administration with inactivated influenza virus (Bergman et al., 1986; Chen et al., 1987; Lazzel et al., 1984) . In our earlier studies (Chen et al., 1987) we examined the effects of intragastric administration of inactivated whole influenza virus vaccine, demonstrating the induction of HA-specific IgA and IgG in pulmonary secretions. HA-specific IgA was the predominant antibody class present in the pulmonary secretions. The present studies extend our previous findings on the activities of secretory antibodies in lungs of mice that were fed with inactivated whole virus influenza vaccine. We report here differences in the effects of intragastric administration of whole virus and split vaccines, persistence of secretory IgA in pulmonary secretions, and specificity of protective efficacy against challenge with live influenza virus. virus vaccines were provided by Connaught Laboratories, Swiftwater, Pa., Wyeth Laboratories, Marietta, Pa. and Parke-Davis, Division of Warner-Lambert Co., Rochester, Mich., U.S.A. The detergents used to manufacture split vaccines were Triton X-100, Tween 80, and tri-N-butyl phosphate with Tween 80, supplied respectively by the aforementioned manufacturers. Formalin-inactivated whole virus vaccines of influenza A/England/864/75/X-49 (H3N2) and A/Chil~/l/83/X-83 (H 1N 1) were obtained from Connaught Laboratories. Their HA contents were measured by the single radial immunodiffusion assay reported by Williams et al. (1980) with 1% Zwittergent R 3-16 detergent (Calbiochem)~ This is used for the currently required vaccine potency determination. Intragastric immunization procedures were as described previously (Chen et al., 1987) . Briefly, gastric acidity of each mouse was pre-neutralized with intragastric administration of 0.1 ml aluminium hydroxide gel antacid (Wyeth Laboratories) and intramuscular injection with 1.2 mg Tagamet (Smith Kline & French Laboratories, Philadelphia, Pa., U.S.A.). The dose (200 txl) of various vaccines was delivered intragastrically with a blunt-ended animal feeding needle (Popper & Sons, New Hyde Park, N.Y., U.S.A.). Lung lavage and serum collection procedures were performed 7 days after booster vaccination (Chen et al., 1987) .
ELISA. The quantification of HA-specific IgA and IgG antibodies in lung lavage fluids and sera was performed using HA-specific and antibody isotype-specific two-step ELISA procedures as described previously (Chert et al., 1987) . Purified HA antigen from influenza A/Philippines/2/82/X-79 virus (Phelan et al., 1980) in carbonate buffer pH 9.6 was coated onto each of the wells in one side of Immulon I plates (Dynatech Laboratories, Alexandria, Va., U.S.A.). The other sides of the plates were coated with carbonate buffer without antigen, serving as control wells. Lung lavage fluids pre-diluted 1:5 and sera pre-diluted 1:10 were inoculated to welts pre-coated with HA or without antigen, and then threefold serial dilutions were performed. Isotype-specific goat anti-mouse IgA or IgG (Southern Biotechnology Associates, Birmingham, Ala., U.S.A.) and alkaline phosphatase-conjugated rabbit anti-goat IgG (Southern Biotechnology) were subsequently incorporated after respective overnight incubation at 4 °C. The substrate, 4-methylumbelliferyl phosphate in 1 M-Tris-HC1 buffer containing 3 rnM-MgC12, pH 9.8 was inoculated and allowed to react for 60 rain at room temperature. The reaction was stopped by adding an equal volume of 0.02 M-EDTA pH 12.0, and the intensity of fluorescence was read by using a Micro-Fluoro Reader (Dynatech). To determine the endpoint, 12 reference wells coated with purified HA were added with goat antimouse IgA and IgG, alkaline phosphatase-conjugated rabbit anti-goat IgG, and with substrate as described above. The mean value plus 3 standard deviations was calculated for the 12 references wells to determine background. The specific endpoint of each sample was determined as the highest dilution in the antigen-coated wells at which the fluorescence intensity exceeded the background value. The geometric mean titre and the 95 confidence interval for each group were calculated. Virus challenge. Virulent influenza A virus was generated by 12 serial passages of human influenza A/Philippines/2/82/X-79 in lungs of mice. The LDs0 of the mouse-adapted strain was 10~'3/ml. Each mouse was inoculated, under ether anaesthesia, by intranasal instillation with 0.1 ml virus suspension containing 5 LDs0 of the challenge virus. The mortality rate was calculated after an observation period of 14 days.
RESULTS

Immunogenicity of vaccines
Our earlier observations (Chen et al., 1987) , that intragastric administration of whole virus inactivated influenza vaccine induces secretion of HA-specific IgA and IgG in lung lavage fluids and a predominance of HA-specific IgG in sera, were confirmed in the present study (Table 1) . By comparison, in each of two experiments, daily doses containing 40 ~tg HA of split virus vaccine from Connaught Laboratories elicited lower, but not significantly different (Kruskal-Wallis test, P > 0.05), pulmonary antibody responses than the whole virus vaccine containing the same amount of HA (Table 1 ). Both vaccines induced higher levels of HAspecific IgA than IgG in lung secretions (13-5 : 1 and 3-6: 1, respectively), but not in sera (1:6.8 and 1 : 1, respectively), when specimens were collected 7 days after the last oral dose in booster immunization. Two other split virus vaccines (Wyeth Laboratories and Parke-Davis) induced antibody titres in lung lavage fluids that were significantly lower than those induced by either the whole virus vaccine or split virus vaccine from Connaught Laboratories.
Dosage effect
The effects of varying the number and strength of doses administered is shown in Table 2 . A series of intragastric inoculations with an inactivated whole virus influenza vaccine containing 40 ~tg HA on each of 4 consecutive days (160 ~tg HA) and a second identical series 3 weeks later induced HA-specific IgA in lung lavage fluids. When the same amount (40 Ixg) was given only * Each mouse received a daily oral dose of a vaccine containing 40 ktg HA for 4 consecutive days in both primary and booster immunizations. Lung lavage fluids and sera were collected 7 days after the last dose of the booster immunization.
t HA-specific antibody titres were measured by ELISA. The responsiveness of both responders and nonresponders were included in the calculation of geometric mean titre and 95 % confidence intervals. The latter are presented in the parentheses.
:~ Significantly higher mean titre than the groups receiving split vaccines from Wyeth Laboratories and ParkeDavis. P < 0.05, by Kruskal-WaUis test.
§ Significantly higher titres than the other groups receiving split virus vaccine. P < 0.05, by Kruskal-Wallis test. twice in each series, the titre of HA-specific IgA produced was lowered. Further reduction to one dose for each immunization series stimulated a significantly lower (P < 0-05, Student's t-test) HA-specific IgA antibody response. When the vaccine strength was doubled to 80 ~tg of HA antigen and administered once intragastrically, the HA-specific IgA antibody secreted in lung fluids was comparable to that produced when 40 ~tg doses of vaccine were given for 2 consecutive days (P > 0.05, Student's ttest). Similarly, when a quadruple strength of the vaccine (160 ~tg) was administered once, it stimulated an HA-specific IgA titre similar to that induced by the same antigenic mass divided into four consecutive daily doses (P > 0.05, Student's t-test).
Antibody persistence
The regimen of intragastric immunization with whole virus vaccine with daily doses of 40 ~tg HA for 4 consecutive days was given as a primary immunization series. An identical regimen was followed 3 weeks later as a booster immunization. Both HA-specific IgA and IgG antibodies were detected in lung lavage fluids 7 days after the booster immunizations. The HAspecific IgA antibody titre declined to approximately one-third of the maximum between 1 and 2 weeks post-vaccination, then persisted throughout the 4 month study period (Table 3 ). The initial titre of HA-specific IgG was lower than IgA in the lung lavage fluids, but remained at a stable level during the 4 month study period. * Each mouse received a daily dose containing 40 ~tg HA of inactivated whole virus influenza vaccine for 4 consecutive days in both the primary and secondary immunization. At each time point, after the fourth dose of the booster immunization, lung lavage fluids from six to eight mice were measured for HA-specific antibody titres by ELISA. Both responders and non-responders were included in the calculation of geometric mean titres as presented.
$-, Not tested. * Each mouse was vaccinated intragastrically daily with a vaccine containing 40 ~tg HA for 4 consecutive days. An identical regimen was followed 3 weeks later.
t No. of mice dead/total no. of mice in each group 14 days after intranasal challenge. Mice were challenged 7 days after the fourth dose of vaccine in the booster immunization.
:~ Significantly lower mortality than in non-immunized mice. P = 2 × 10 -a, by Fisher's exact test. § Significantly lower mortality than in non-immunized mice. P = 0.005, by Fisher's exact test.
Protective immunity
Adult mice were immunized intragastrically for 4 consecutive days with a whole virus vaccine containing a daily dose of 40 lxg HA of the various strains or subtypes: A/Philippines/2/82/X-79 (H3N2), A/England/864/75/X-49 (H3N2) or A/Chile/1/83/X-83 (H1N1), respectively. Three weeks later, a booster immunization following an identical regimen was administered. One week after the booster immunization mice were challenged intranasally with 5 LDs0 of virulent mouse-adapted influenza A/Philippines virus as shown in Table 4 . Twenty-one non-immunized mice suffered a mortality rate of 90~o after virus challenge, but 15 mice immunized with a vaccine strain homologous to the challenge virus were completely protected. Vaccine containing influenza A/England conferred 50~ protection against mortality while the unrelated (HI) subtype vaccine did not protect significantly against mortality.
DISCUSSION
In the present study two of the three split virus vaccines administered intragastrically to seronegative adult mice induced significantly lower titres of secretory antibodies in lung lavage fluids than those induced by the whole virus vaccine. The other split virus vaccine had an immunogenicity comparable to that of the whole virus vaccine (P > 0.05, Kruskal-Wallis test) (Theodorsson-Norheim, 1986 ). The differences in antigenicity between these vaccines may be due in part to the various preparation methods employed. The lower immunogenicity of two of the split virus vaccines may be attributable to increased susceptibility to denaturation or digestion by proteases present in the gastrointestinal tract.
Earlier we reported induction of synthesis of antibodies in the lung when doses of whole virus vaccine were administered daily for 4 consecutive days for both the primary and booster immunizations (Chen et al., 1987) . The results of the present study indicate that a single vaccine dose equivalent in mass to the total of the four divided doses induced comparable lung antibody titres. Thus, the vaccine strength is a critical factor for induction of virus-specific lung antibodies when vaccine is given intragastrically. These results have implications with respect to the potential practicality of intragastric or oral immunization.
Oral vaccination requires both a substantial amount of antigenic content in the vaccine and great care to protect against its degradation by gastric acidity. Development of an enteric coating to protect the antigenicity of the vaccine may assure its efficacy. Furthermore, future improvements in antigen presentation, such as the use of adjuvants, may reduce the necessary dosages of vaccine. Liew et al. (1984) have shown that the presence of virus-specific secretory antibodies at the pulmonary mucosa confers effective protection against influenza virus infection. The persistence of lung antibodies should render lasting protective immunity (Clements & Murphy, 1986) . We observed that the highest titre of HA-specific IgA in lung lavage fluids occurred 1 week after the second course of intragastric immunization. Although the HA-specific IgA titre declined rapidly in the following week, it was maintained at a constant level for 4 months afterwards. In contrast, HA-specific IgG in lung secretions was sustained at the same titre within the study period of 4 months. A similar observation has been made, in that a heightened IgA titre in salivary secretions occurs at 1 to 2 weeks after intragastric vaccination with killed Streptococcus mutans, and remains significantly elevated for 11 weeks (Challacombe, 1983) . Lung antibody titres against influenza virus persist for at least 6 weeks after intranasal immunization with inactivated influenza virus vaccine of children with prior infection (Wright et al., 1983) . Thus, the mucosal immunity induced by intragastric administration persisted in a similar pattern to that stimulated via the respiratory tract immunization. The reason for the decay of IgA, but not IgG, in lung secretions is unclear.
The constant antigenic drift of influenza virus presents special problems for effective control unless the parenteral vaccine contains the same antigenic determinants as the circulating virus strains. Although the HA of influenza A/England is antigenically distant from that of influenza A/Philippines, lung antibodies induced by the former offered a significant degree of crossprotection against challenge by the latter. The secretory IgA in lung lavage fluids, but not monomeric IgA or IgG, prevents the attachment of neutralized influenza virus to cell surface (Taylor & Dimmock, 1985) . The unique neutralizing activity attributable to secretory IgA and the presence of high concentrations of secretory IgA antibodies in lungs after intragastric immunization might contribute to a broad spectrum of efficacy.
This study extends earlier observations documenting induction of secretory antibodies by intragastric administration of inactivated influenza vaccine. This approach to immunization appeared practical, since two doses 1 month apart were immunogenic. Differences in immunogenicity of different preparations were noted, possibly relating to the extent of solubilization of the proteins. The immunity induced by this method was broadly reactive, since mice were protected against lethal infection with a virus strain of the same subtype but antigenically variant from the vaccine strain. Thus, intragastric immunization may be a valuable means of inducing protective secretory immunity.
